Resistance Training in Lung Cancer Patients on Chemotherapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01130714 |
Recruitment Status :
Completed
First Posted : May 26, 2010
Last Update Posted : August 20, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Inflammation Lung Cancer | Behavioral: Exercise | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | July 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Resistance training
Group assigned to complete resistance training during duration of chemotherapy.
|
Behavioral: Exercise
Resistance training with resistance bands. |
No Intervention: Control
Usual care.
|
- Systemic inflammation measured by c-reactive protein. [ Time Frame: 12 weeks ]
- Chemotherapy completion [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically diagnosed with lung cancer
- Stage I, II, or III
- Eligible for chemotherapy with curative intent
- 21 years of age or older
- Approval to participate in study by treating oncologist or family physician
Exclusion Criteria:
- Unstable cardiac disease
- Untreated bone or brain metastases

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01130714
United States, North Carolina | |
Leo Jenkins Cancer Center | |
Greenville, North Carolina, United States, 27834 |
Principal Investigator: | Kristina H Karvinen, PhD | East Carolina University |
Responsible Party: | Kristina Karvinen, Assistant Professor, East Carolina University |
ClinicalTrials.gov Identifier: | NCT01130714 |
Other Study ID Numbers: |
UMCIRB 09-0725 |
First Posted: | May 26, 2010 Key Record Dates |
Last Update Posted: | August 20, 2015 |
Last Verified: | August 2015 |
inflammation chemotherapy lung cancer |
Lung Neoplasms Inflammation Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Pathologic Processes |